Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Celgene
Age
18–any
Sex
ALL
Healthy volunteers
Not accepted
You may be eligible if
Participants must satisfy the following criteria to be enrolled in the study:
Inclusion
Participant is ≥ 18 years of age at the time of signing the ICF.
Participant has a history of multiple myeloma (MM) with relapsed and/or refractory disease
Participant must have measurable disease.
Participant has an Eastern Cooperative Oncology Group Performance Status (ECOG PS) of 0 or 1.
You may not be if
Participant has symptomatic central nervous system involvement of MM.
Participant had a prior autologous stem cell transplant ≤ 3 months prior to starting CC-99712.
Participant had a prior allogeneic stem cell transplant with either standard or reduced intensity conditioning ≤ 6 months prior to starting CC-99712 or is on systemic immunosuppression for graft-versus host disease.
Subject is a pregnant or lactating female.
Subject has known human immunodeficiency virus (HIV) infection.
Subject has active hepatitis B or C (HBV/HCV) infection.
Clareo Health | A Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Participants With Relapsed and Refractory Multiple Myeloma
